The decision by TCR2 Therapeutics to establish a presence at the Cell & Gene Therapy Catapult manufacturing centre is a major international vote of confidence in the UK life sciences sector. The Cell and Gene Therapy Catapult manufacturing centre is a world-leading facility, bringing the manufacture of pioneering treatments closer to patients. The decision recognises the level and maturity of government investment into UK manufacturing capability and the associated supply chain. UK Research and Innovation, through the government’s Industrial Strategy Challenge Fund, backs this crucial component of the modern Industrial Strategy, building the jobs and industries of tomorrow. We have underlined our support by also funding three new Advanced Therapy Treatment Centres to complement the work of the manufacturing centre. Working across the UK, this network will support the roll-out of cell and gene therapies, bringing together expert clinicians, researchers, scientists, developers and private companies to demonstrate the benefits for patients. The CGT Catapult manufacturing centre in Stevenage, opened in April 2018, is backed by more than £60 million of government investment, including funding from Innovate UK and the Industrial Strategy Challenge Fund (ISCF). TCR2 joins advanced therapy companies Adaptimmune, Autolus, Cell Medica, and Freeline.Working with the manufacturing centre are the three UK Advanced Therapies Treatment Centres, which were awarded £21 million in through the ISCF Medicines Manufacturing challenge. The centres are collaborative ventures between industry, academic and NHS partners. They comprise the Innovate Manchester Advanced Therapy Centre Hub (iMATCH), the Midlands-Wales Advanced Therapy Treatment Centre (MW-ATTC, comprising Birmingham, Wales and Nottingham) and the Northern Alliance Advanced Therapies Treatment Centre (NAATTC, comprising Scotland, Newcastle and Leeds). By choosing to work with the Cell & Gene Therapy Catapult manufacturing centre, TCR2 Therapeutics demonstrates to the world that the UK is a global leader in this sector. Advanced cell and gene therapies show great promise in treating conditions such as cancer. It is vital to support research and development that could result in huge improvements in patient outcomes. Boosted by investment through the government’s modern Industrial Strategy and the life sciences sector deal, the UK can realise both the commercial and societal benefits from these advances in this vital and thriving sector. Innovate UK, part of UK Research and Innovation, welcomed today the announcement that immunotherapy company, TCR2 Therapeutics, is to become the first US organisation to work with the Cell and Gene Therapy (CGT) Catapult at its Stevenage manufacturing centre. TCR2 has selected the facility to establish a site for global manufacturing and capability development to advance novel T cell receptor therapies for patients suffering from cancer.Dr Ian Campbell, Interim Executive Chair, Innovate UK said: Dr Kath Mackay, Interim Director – Ageing Society, Health & Nutrition, Innovate UK, added:
Tag Archives: 娱乐地图PO
Bakery supplier Lantmännen Unibake UK has appointed Richard Stowey to head its UK site operations.Stowey will be responsible for all UK operations, including end-to-end supply chain, technical, procurement and capital investment programmes. He will also look after the company’s two high-output UK factories, based in Milton Keynes and Bedford respectively.His most recent experience is associated with managing large-scale new factory build projects for Noble Foods and Dairy Crest.“I want to spend this year focusing on our factory and, ultimately, the things we are measured by,” said Stowey. “To achieve this, we’re making our senior team far more visible and accessible in the bakery, and giving the teams a more defined drumbeat to operate to, making sure we are all working together as one cohesive and united team.”Stowey said he was also looking forward to the firm’s capital investment into its burger bun and bread lines, which he believed would help “expand capacity to meet customer demand” and improve efficiency.Stowey previously worked in site general management positions with Northern Foods for seven years, followed by meals and sandwich manufacturing experience as operations director at Buckingham Foods and Premier Foods.